卡瑞利珠联合靶向治疗原发性肝癌患者疗效及安全性分析*

doi:10.3969/j.issn.1672-5069.2024.05.030

摘要/Abstract

摘要： 目的观察卡瑞利珠单抗联合索拉非尼治疗晚期原发性肝癌(PLC)患者的临床疗效和安全性。方法 2021年1月～2023年1月我科收治的62例晚期肝细胞癌(HCC)患者,其中31例观察组接受卡瑞利珠单抗联合索拉非尼治疗,另31例对照组仅接受索拉非尼治疗,观察两组近期疗效和不良反应。结果观察组客观缓解率(ORR)为41.9%,疾病控制率(DCR)为87.1%,均显著高于对照组的16.1%和64.5%(P<0.05);截止到2023年9月30日,观察组9例(29.0%)生存,对照组8例(25.8%,P>0.05)生存;观察组中位无进展生存期(PFS)为7.3个月【95%置信区间(CI):5.66～8.94),中位总体生存期(OS)为15.6个月(95% CI:11.84～19.34)】,对照组分别为4.9个月(95%CI:3.92～5.88)和10.1个月(95% CI:8.59～11.71),差异均有统计学意义(P<0.05);观察组免疫性甲状腺炎、反应性皮肤毛细血管增生症和疲乏发生率分别为25.8%、32.2%和64.5%,均显著高于对照组的0.0%、0.0%和35.5%(P<0.05)。结论应用卡瑞利珠单抗联合索拉非尼治疗晚期HCC患者能获得较好的近期疗效,延长患者生存期,不良反应可控,值得临床进一步验证。

关键词: 原发性肝癌, 卡瑞利珠, 索拉非尼, 治疗, 安全性

Abstract: Objective This study was aimed at investigating clinical efficacy and safety of camrelizumab and sorafenibcombination therapy in the treatment of patients with advanced hepatocellular carcinoma (aHCC). Method 62 consecutive patients with aHCC were encountered in our hospital between January 2021 to January 2023, and we assigned them to receive camrelizumab and sorafenib combination or to receive sorafenib alone treatment. All patients were followed-up to September 30, 2023. Results Objective response rate was 41.9%, and disease control rate was 87.1%, both much higher than 16.1% and 64.5%(P<0.05) in the control; up to September 30, 9 patients (29.0%) in the combination group and 8 patients (25.8%, P>0.05) in sorafenib-treated group survived; in combination group, median progression free survival was 7.3 mon (95% CI:5.66-8.94), and overall survival was 15.6 mon(95% CI:11.84-19.34), while in the control, they were 4.9 mon(95%CI:3.92-5.88)and 10.1 mon(95% CI:8.59-11.71), both significantly different between the two groups (P<0.05);the incidence of immune thyroiditis was 25.8%, reactive cutaneous capillary hyperplasia was 32.2% and fatigue was 64.5% in the combination group, much higher than 0.0%, 0.0% and 35.5% (P<0.05) in the control. Conclusion Combination of camrelizumab and sorafenib in the treatment of patients with aHCC is encouraging, which might prolong survival and the adverse effect is under control.

Key words: Hepatocelluler carcinoma, Camrelizumab, Sorafenib, Therapy, Safety

王冬梅, 李俊, 徐滨, 马欢, 徐兴军, 芦东徽. 卡瑞利珠联合靶向治疗原发性肝癌患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 765-768.

Wang Dongmei, Li Jun, Xu Bin, et al. Efficacy and safety of camrelizumab and sorafenib combination therapy in the treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2024, 27(5): 765-768.

参考文献

[1] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortalityin 2018:GLOBOCAN sources and methods. Int J Cancer, 2019,144(8):1941-1953.
[2] Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer, 2015,3:36.
[3] 李灵, 贺剑, 谢义星, 等. TACE-HAIC-靶向-免疫四联治疗中晚期肝细胞癌的回顾性对照研究. 中华肝脏病杂志, 2022, 30(9): 939-946.
[4] Zhou T, Wang X, Cao Y, et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res, 2022,22(1):1367.
[5] Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol, 2022,23(1):77-90.
[6] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2022年版).中华肝脏病杂志,2022,30(4):367-388.
[7] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol, 2018,69(1):182-236.
[8] Simcock R, Wright J. Beyond performance status. Clin Oncol (R Coll Radiol), 2020,32(9):553-561.
[9] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009,45(2):228-247.
[10] Xie L, Qian Z, Xu J. Clinical intervention effect of TACEcombined with 3DCRT in patients with primary liver cancer. Am J Transl Res,2021, 13(7):7960-7967.
[11] 王瑞华,胡明,杨之雨,等. 2000-2020年全球肝癌发病和死亡状况和未来流行趋势: GLOBOCAN数据分析.中华肝脏病杂志, 2023, 31(3): 271-280.
[12] 南月敏, 苗同国. 肝细胞癌靶向及免疫治疗进展. 中华肝脏病杂志, 2022, 30(9): 905-911.
[13] Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol, 2021, 18(1):112-127.
[14] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellularcarcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial,Lancet, 2017,389(10088):2492-2502.
[15] Feng D, Hui X, Shi-Chun L, et al. Initial experience of anti-PD1 therapy withnivolumab in advanced hepatocellular carcinoma. Oncotarget, 2017,8(57):96649-96655.
[16] 杜尚云,翁莉,武敏. TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究. 实用肝脏病杂志, 2023,26(1):116-119.
[17] Fukui N, Golabi P, Otgonsuren M, et al. Hospice care in medicare patients with primary liver cancer: the impact on resource utilisation and mortality. Aliment Pharmacol Ther, 2018,47(5):680-688.
[18] Zhang Z, Li M, Zhang Z. lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p. Onco Targets Ther, 2020,13:1343-1354.
[19] Xi Z, Si J, Nan J. LncRNA MALAT1 potentiates autophagy associated cisplatin resistance by regulating the microRNA 30b/autophagy related gene 5 axis in gastric cancer. Int J Oncol, 2019,54(1):239-248.
[20] 曹洪祥, 廖锐, 贺强, 等. 肝动脉灌注化疗联合免疫靶向治疗在晚期肝细胞癌中的临床疗效. 中华消化外科杂志, 2021, 20(S2): 41-44.
[21] Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet, 2023,402(10408):1133-1146.
[22] 刘金, 曹刚, 张根山, 等. 卡瑞利珠单抗联合阿帕替尼治疗D-TACE后进展的中晚期肝癌的初步疗效及安全性分析. 中华医学杂志, 2021, 101(29): 2304-2309.
[23] Deng QJ, Xie LQ, Li H. Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. Life Sci, 2016,157:38-44.
[24] Li Y, Wu Z, Yuan J, et al. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. Cancer Lett, 2017,395:31-44.
[25] 陈鹏,刘欢. 免疫检查点抑制剂治疗晚期肝细胞癌患者研究进展. 实用肝脏病杂志, 2023,26(3):453-456.
[26] Chen X, Ma L, Wang X, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med, 2019,16(1):173-181.
[27] Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical hodgkin lymphoma. J Clin Oncol, 2019,37(17):1479-1489.

卡瑞利珠联合靶向治疗原发性肝癌患者疗效及安全性分析^*

Efficacy and safety of camrelizumab and sorafenib combination therapy in the treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[2]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.
[3]	中国医药生物技术协会慢病管理分会肝病学组. 双环醇防治肝脏炎性损伤多学科专家共识[J]. 实用肝脏病杂志, 2024, 27(5): 659-668.
[4]	彭麟, 杨春, 李兴泉. 聚乙二醇干扰素α-2b联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 677-680.
[5]	冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
[6]	黎防, 杨宏飞, 张青. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(5): 685-688.
[7]	刘雅光, 胡连智, 董一侠, 刘洋. 抗病毒治疗的基因1b型慢性丙型肝炎患者疗效及其血清γ-干扰素和白细胞介素-10水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 689-692.
[8]	莫伟斌, 张清友, 黄晓涵, 欧阳婉爱. 达诺瑞韦联合拉维达韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 693-696.
[9]	高怡, 沈小雪, 夏素芹, 张洁, 朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(5): 709-712.
[10]	蒋叶舟, 花霞, 陈国飞, 朱青蓝, 蔡明月. 自身免疫性肝炎患者血清瘦素、外周血调节性T细胞和Th17细胞水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 713-716.
[11]	朱家瑞, 葛绍锋, 叶桂云, 黄远茂. 自身免疫性肝炎患者外周血NLR和nCD64指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 717-720.
[12]	王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 721-724.
[13]	王秀娟, 朱贺, 张茹梦, 常文绘, 刘玉玉. 泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者不同减量方法的效果研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 729-732.
[14]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.
[15]	田琳, 康颖, 崔洁, 石颖鹏. 内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 745-748.